Pulsed field ablation
Sphere-360™ catheter received CE Mark
Exclusively integrated with Affera™ mapping and ablation system
All-in-one:
single-shot PFA catheter with 10 Fr shaft
Tissue-conformable lattice tip
Rotation-free ablation
Adjustable shape:
fully expandable to 34 mm
The Sphere-360™ European study was a prospective, single-arm, multicenter trial designed to evaluate safety, effectiveness, and lesion durability of the Sphere-360™ catheter when used for the treatment of symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients (n = 100). Results of this study are outlined in the manuscript ”One-year outcomes of a conformable single-shot pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation” linked below.
This study was a prospective, single-arm trial evaluating the safety, efficacy, and durability of the Sphere-360™ PFA catheter for the treatment of PAF.
Freedom from AF/AT/AFL
AA burden with continuous monitoring for recurrent patients†
Daily AA burden (%)
PV durability‡
PFA lesion durability demonstrated by invasive remapping 75 days post-ablation
0
primary adverse events§
4.0 ± 1.3
applications per PV
58 min
procedure time¶
22 min
LA dwell time
< 12 min
PV transpired time
< 7 min
fluoroscopy time#
PVI: Pulmonary vein isolation; AF: Atrial fibrillation; AT: Atrial tachycardia; AFL: Atrial flutter; AA: Atrial arrhythmia; PV: Pulmonary vein; LA: Left atrial.
† N = 15 patients monitored with ILR in PULSE3 cohort; and AF burden measured for 3 recurrent patients.
‡ Fifty patients treated with the PULSE3 optimized and most recent waveform configuration, 40 of which completed the optional remapping procedure.
§ See manuscript for all adverse event incidence.
◊ See manuscript for full listing of procedural characteristics.
¶ Includes 20-minute wait time.
# Four patients done with 0 fluoroscopy workflow, 26 patients with less than or equal to 3 minutes of fluoroscopy.
The material on this website should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).
Please note that the intended use of a product may vary depending on geographical approvals.
See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.
For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.
If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com.
Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices. For any further information, contact your local Medtronic representative.
Medtronic medical devices marketed in Spain are in compliance with the Spanish legislation in force.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.